{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:45:17Z","timestamp":1748972717411},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"DOI":"10.2146\/ajhp120599","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T19:58:26Z","timestamp":1376423906000},"page":"1518-1527","source":"Crossref","is-referenced-by-count":13,"title":["Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants"],"prefix":"10.1093","volume":"70","author":[{"given":"Josephine","family":"Mauskopf","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costel","family":"Chirila","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Graham","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris D.","family":"Gersten","sequence":"additional","affiliation":[{"name":"The EMMES Corporation, Rockville, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Adult Blood and Marrow Stem Cell Transplant Program, and Professor of Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital\/Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M. Y.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Divisions of Blood and Marrow Transplantation and Infectious Diseases, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation\u2013Oncology, Infectious Diseases Program, Chief, Medical Mycology Research Laboratory, and Professor of Medicine, Microbiology and Immunology, and Pediatrics, Weill Cornell Medical Center of Cornell University, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary H.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, and Professor of Medicine and Chief Scientific Director, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Kurtzberg","sequence":"additional","affiliation":[{"name":"Carolinas Cord Blood Bank, Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program, and Director, Pediatric Blood and Marrow Transplant Program, Duke University, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieren A.","family":"Marr","sequence":"additional","affiliation":[{"name":"Transplant and Oncology Infectious Diseases Program, School of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Florida College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Leather","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607512462000_b1-0701518","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1592\/phco.29.11.1306","article-title":"Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts","volume":"29","author":"McCoy","year":"2009","journal-title":"Pharmacotherapy."},{"key":"2019041607512462000_b2-0701518","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019041607512462000_b3-0701518","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood."},{"key":"2019041607512462000_b4-0701518","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis."},{"key":"2019041607512462000_b5-0701518","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood."},{"key":"2019041607512462000_b6-0701518","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/11588370-000000000-00000","article-title":"Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence","volume":"29","author":"Pechlivanoglou","year":"2011","journal-title":"Pharmacoeconomics."},{"key":"2019041607512462000_b7-0701518","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/11206800-000000000-00000","article-title":"Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts","volume":"29","author":"Lyseng-Williamson","year":"2011","journal-title":"Pharmacoeconomics."},{"key":"2019041607512462000_b8-0701518","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med."},{"key":"2019041607512462000_b9-0701518","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med."},{"key":"2019041607512462000_b10-0701518","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Van Burik","year":"2004","journal-title":"Clin Infect Dis."},{"issue":"9","key":"2019041607512462000_b11-0701518","first-page":"1","article-title":"United States life tables, 2004","volume":"56","author":"Arias","year":"2007","journal-title":"Natl Vital Stat Rep."},{"key":"2019041607512462000_b12-0701518","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol."},{"key":"2019041607512462000_b13-0701518","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2146\/ajhp070588","article-title":"Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia","volume":"65","author":"Collins","year":"2008","journal-title":"Am J Health-Syst Pharm."},{"key":"2019041607512462000_b14-0701518","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1524-4733.2008.00486.x","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States","volume":"12","author":"O\u2019Sullivan","year":"2009","journal-title":"Value Health."},{"key":"2019041607512462000_b15-0701518","volume-title":"Red Book Online [Internet database, through Micromedex 2.0]","year":"2011"},{"key":"2019041607512462000_b16-0701518","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","article-title":"The direct cost and incidence of systemic fungal infections","volume":"5","author":"Wilson","year":"2002","journal-title":"Value Health."},{"key":"2019041607512462000_b17-0701518","unstructured":"McDowell MA Fryar CD Ogden CL . Anthropometric reference data for children and adults: United States, 2003\u20132006. www.cdc.gov\/nchs\/data\/nhsr\/nhsr010.pdf (accessed 2011 Dec 21)."},{"key":"2019041607512462000_b18-0701518","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","article-title":"Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane","volume":"7","author":"Briggs","year":"1998","journal-title":"Health Econ."},{"key":"2019041607512462000_b19-0701518","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000313696","article-title":"Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland","volume":"78","author":"Greiner","year":"2010","journal-title":"Oncology."},{"key":"2019041607512462000_b20-0701518","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00520-010-1022-7","article-title":"Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis","volume":"19","author":"Dranitsaris","year":"2011","journal-title":"Support Care Cancer."},{"key":"2019041607512462000_b21-0701518","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.2008.01141.x","article-title":"Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands","volume":"81","author":"Stam","year":"2008","journal-title":"Eur J Haematol."},{"issue":"suppl 1","key":"2019041607512462000_b22-0701518","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jval.2011.05.032","volume":"14","author":"Rely","year":"2011","journal-title":"Value Health."},{"key":"2019041607512462000_b23-0701518","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/jac\/dkq076","article-title":"Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia","volume":"65","author":"Al-Badriyeh","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"2019041607512462000_b24-0701518","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2146\/ajhp110149","article-title":"Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease","volume":"69","author":"O\u2019Sullivan","year":"2012","journal-title":"Am J Health-Syst Pharm."},{"key":"2019041607512462000_b25-0701518","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.clinthera.2008.04.020","article-title":"Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"Schonfeld","year":"2008","journal-title":"Clin Ther."},{"key":"2019041607512462000_b26-0701518","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.clinthera.2009.05.011","article-title":"Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea","volume":"31","author":"Sohn","year":"2009","journal-title":"Clin Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/17\/1518\/28456474\/ajhp1518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T22:30:00Z","timestamp":1596321000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/17\/1518\/5112349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120599","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9,1]]},"published":{"date-parts":[[2013,9,1]]}}}